AdaptHealth Corp. Q2 FY2025 earnings call

Management Statement and Operational Highlights:

• Non-acquired growth: Signed a 5-year $1B+ contract with a major health system for home medical equipment/supplies, capitation model covering 10M+ members, boosting capitated revenue to at least 10% of total. Segments like Respiratory, Diabetes, Sleep showing growth/improvement with operational changes (e.g., Respiratory sales incentive changes, Diabetes new starts/resupply retention, Sleep standardized scheduling/order intake).
• Enhancing profitability: Rolling out standard field operating model with standardized spans/layers/roles, regional centralization of functions, leveraging tech/AI for productivity (automating call handling/order intake), scaling myAPP for self-service.
• Balance sheet: Reduced debt by $150M in Q2, net debt $1.8B, net leverage 2.81x, tracking to 2.5x target, with progress on deleveraging.

Segment Performance:

• Sleep Health: Q2 net revenue increased 0.9% vs prior year to $334.7 million, included noncash impact from revenue mix shift. Starts were ~128,000 (highest in 2 years), census 1.7 million patients.
• Respiratory Health: Net revenue increased 5.6% from prior year to $170.5 million, strong oxygen starts, oxygen census 329,000 (new Q2 record).
• Diabetes Health: Net revenue declined 4.1% vs prior year to $145.0 million, but showed recovery signs with improvement in starts and resupply retention.
• Wellness at Home: Net revenue declined 7.2% from prior year to $150.3 million, including impact from asset dispositions.

Guidance:

• Full year 2025: Maintaining revenue midpoint $3.18B-$3.26B, reducing adjusted EBITDA guidance to $642M-$682M, maintaining free cash flow guidance $170M-$190M.
• Q3 2025: Expected revenue ~$800M (largely flat vs Q3 2024), adjusted EBITDA margin 20%-21%.
• Capitulated partnership: Expected to generate at least $200M annual revenue, ramping in 2026 with infrastructure investments underway.

Risks:

• CMS proposed rule on home health/DME bidding, potential cost pressure and industry consolidation, though scale helps.
• Uncertainty around bidding program details and impact on industry operators.
• Payer rate negotiations slipping into 2026 despite revised adjusted EBITDA guidance.

Q: Eric Coldwell from Baird asked about the $200 million minimum annual revenue from the capitated deal, including if it's anticipated to grow, details on ramp and kick-in.

A: Suzanne Foster and Jason Clemens responded that the deal will ramp in 2026, starting with first patients in Q1, with service to over 10M members throughout 2026 and full service by 2027, and it's a per member per month type agreement with potential for growth over time.

Q: Philip Chickering from Deutsche Bank asked about EBITDA guidance change and M&A environment.

A: Jason Clemens said the $20 million EBITDA guidance change is due to timing of payer rate negotiations slipping into 2026 and infrastructure needs for the capitated deal, and Suzanne Foster discussed M&A focus on core competencies of Sleep and Respiratory with disciplined approach.

Q: Michael Murray from RBC Capital Markets asked about M&A environment and Diabetes revenue outlook.

A: Suzanne Foster discussed M&A interest in core segments with discipline, and Suzanne Foster and Jason Clemens noted Diabetes showing momentum with expected positive year-over-year trends in back half of 2025.